Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Midatech Pharma plc is a biotechnology business based in the US. Midatech Pharma shares (MTP) are listed on the NASDAQ and all prices are listed in US Dollars. Midatech Pharma employs 18 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $1.13 |
|---|---|
| 52-week range | $1.02 - $3.83 |
| 50-day moving average | $1.36 |
| 200-day moving average | $1.79 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.89 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.13 from 2022-01-18
| 1 week (2022-01-12) | -4.24% |
|---|---|
| 1 month (2021-12-17) | -7.38% |
| 3 months (2021-10-19) | -38.92% |
| 6 months (2021-07-19) | -38.59% |
| 1 year (2021-01-19) | -51.29% |
|---|---|
| 2 years (2020-01-17) | 25.56% |
| 3 years (2019-01-18) | 650.33% |
| 5 years (2017-01-19) | 2.9658 |
| Revenue TTM | $576,000 |
|---|---|
| Gross profit TTM | $-3,985,000 |
| Return on assets TTM | -19.06% |
| Return on equity TTM | -190.94% |
| Profit margin | 0% |
| Book value | $0.30 |
| Market capitalisation | $15.6 million |
TTM: trailing 12 months
We're not expecting Midatech Pharma to pay a dividend over the next 12 months.
Midatech Pharma's shares were split on a 1:5 basis on 2 March 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Midatech Pharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Midatech Pharma shares which in turn could have impacted Midatech Pharma's share price.
Over the last 12 months, Midatech Pharma's shares have ranged in value from as little as $1.015 up to $3.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Midatech Pharma's is 1.5846. This would suggest that Midatech Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom. .
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.